Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): ...

    2026-01-01

    DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Mechanistic Evidence, Benchmarks, and Workflow Integration

    Executive Summary: DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a validated anion transport inhibitor, blocking ClC-Ka chloride channels with an IC50 of 100 μM and bacterial ClC-ec1 exchangers at approximately 300 μM, under standardized in vitro conditions (APExBIO B7675). DIDS modulates TRPV1 channel function in dorsal root ganglion neurons, enhancing agonist-induced currents (pH < 6.0, 24°C) (source). In vascular models, DIDS causes vasodilation in pressure-constricted cerebral artery smooth muscle with an IC50 of 69 ± 14 μM. In vivo, DIDS enhances hyperthermia-induced tumor growth suppression and ameliorates ischemia-hypoxia neurotoxicity by inhibiting ClC-2 and reducing ROS, iNOS, TNF-α, and caspase-3 positive cells in neonatal rats (Conod et al., 2022). The compound is insoluble in water, ethanol, and DMSO but dissolves in DMSO above 10 mM when warmed to 37°C. Stock solutions require storage below –20°C and are unsuitable for extended storage in solution (APExBIO B7675).

    Biological Rationale

    DIDS is a small-molecule inhibitor designed to target anion transport, specifically chloride channels. Chloride ions (Cl−) regulate membrane potential, synaptic transmission, cell volume, and epithelial transport. Abnormal chloride channel activity is implicated in tumorigenesis, ischemic injury, neurodegeneration, and vascular dysregulation. By inhibiting ClC family channels (ClC-Ka, ClC-ec1, ClC-2), DIDS modulates these key physiological and pathological processes. Its ability to block anion flux is leveraged in models of cancer metastasis, ischemia-induced brain injury, and cerebral vasodilation. The product is widely used to dissect chloride channel function in translational and mechanistic studies (see advanced use-cases). This article extends existing guides by providing atomic, quantitative, and protocol-level integration details.

    Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

    DIDS covalently modifies lysine residues on chloride channel proteins, resulting in non-competitive, irreversible inhibition of anion conductance (Conod et al., 2022). For ClC-Ka, DIDS exhibits an IC50 of 100 μM in patch-clamp assays (pH 7.4, 25°C). In bacterial ClC-ec1 Cl−/H+ exchangers, the IC50 is approximately 300 μM. DIDS also impacts TRPV1 channels in dorsal root ganglion neurons, potentiating channel function when co-applied with capsaicin or low pH, implying allosteric modulation. In vascular tissue, DIDS reduces spontaneous transient inward currents (STICs) and mediates vasodilation. In ischemia models, DIDS inhibits ClC-2 channels, reducing downstream oxidative and apoptotic markers. The compound’s effects are concentration-dependent, and its actions are typically rapid and robust within in vitro and ex vivo preparations. According to APExBIO, optimal DIDS activity requires proper dissolution and temperature control (product details).

    Evidence & Benchmarks

    • DIDS inhibits ClC-Ka chloride channels with an IC50 of 100 μM (patch-clamp, pH 7.4, 25°C) (APExBIO B7675).
    • Bacterial ClC-ec1 Cl−/H+ exchanger blocked by DIDS with an IC50 of ~300 μM (reconstituted system, physiological buffer) (APExBIO B7675).
    • Vasodilation in pressure-constricted cerebral artery smooth muscle occurs with an IC50 of 69 ± 14 μM (ex vivo, 37°C) (APExBIO B7675).
    • DIDS reduces STICs in muscle cells in a concentration-dependent manner (isolated muscle, 22–24°C) (mechanistic overview).
    • Potentiation of TRPV1 currents in DRG neurons when co-applied with capsaicin or acidic pH (Conod et al., 2022).
    • In vivo, DIDS enhances hyperthermia-induced tumor growth suppression and prolongs tumor growth delay when combined with amiloride (murine model, 42°C, 30 min) (Conod et al., 2022).
    • DIDS ameliorates ischemia-hypoxia-induced white matter injury in neonatal rats by inhibiting ClC-2 and decreasing ROS, iNOS, TNF-α, and caspase-3 positive cells (in vivo, P7 rat, 24 h recovery) (Conod et al., 2022).
    • DIDS is insoluble in water, ethanol, and DMSO, but dissolves in DMSO above 10 mM at 37°C or with ultrasonication (APExBIO B7675).

    Applications, Limits & Misconceptions

    DIDS is primarily used in research applications involving chloride channel inhibition, vascular physiology, neuroprotection, and cancer hyperthermia studies. It is a benchmark tool for validating chloride channel function and for modeling disease processes where Cl− flux is critical. For example, DIDS is instrumental in dissecting mechanisms of tumor cell death and metastasis (Conod et al., 2022). The compound is also used in neurodegenerative disease models to prevent white matter injury through inhibition of ClC-2. However, DIDS’s irreversible and non-selective inhibition can affect multiple anion channels, necessitating careful control experiments. This article builds on prior guides (see comparative workflows), but provides more granular, quantitative, and protocol-level integration guidance.

    Common Pitfalls or Misconceptions

    • DIDS does not selectively inhibit a single chloride channel subtype; off-target effects are possible at higher concentrations.
    • It is ineffective in aqueous, ethanol, or DMSO below 10 mM; incomplete dissolution can result in inconsistent results.
    • DIDS is not suitable for long-term storage in solution; hydrolysis and loss of activity may occur above –20°C or after multiple freeze-thaw cycles.
    • It does not reverse advanced neurodegeneration or tumor burden in established disease; best used as a mechanistic probe in early-phase or acute models.
    • DIDS is not a clinical therapeutic; all uses are for research purposes only, as emphasized by APExBIO and peer-reviewed studies.

    Workflow Integration & Parameters

    For optimal solubility, dissolve DIDS above 10 mM in DMSO, warming to 37°C or using an ultrasonic bath. Prepare fresh aliquots for each experiment. Store stock solutions below –20°C; do not use after extended storage or multiple freeze-thaw cycles. In patch-clamp or bath application protocols, apply DIDS at empirically determined concentrations (e.g., 100 μM for ClC-Ka, 69 μM for vascular dilation) and confirm channel inhibition via appropriate positive and negative controls. For in vivo models, DIDS is administered via routes and dosages detailed in published protocols (e.g., 0.5–2 mg/kg, intraperitoneal, 30 min prior to insult). Quality controls include verifying solubility, pH, and lack of visible precipitate. This article updates and extends actionable guidance found in atomic guidance for channel integration.

    Conclusion & Outlook

    DIDS remains a foundational tool for dissecting chloride channel physiology and pathophysiology. Its robust, irreversible inhibition profile enables precise mechanistic interrogation in cancer, neuroprotection, and vascular research. Limitations in selectivity and solubility require diligent protocol adherence and control design. For researchers requiring validated, quantitative, and protocol-driven integration of chloride channel inhibition, DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) from APExBIO offers a reliable and standardized reagent. Future advances may involve engineering derivatives with enhanced selectivity or solubility, but DIDS sets the current gold standard.